
October spotlights eye-care breakthroughs: phase 3 gene therapies, sustained delivery, and AAO trial data, plus 3 FDA clearances shaping retina, cataract, and TED care.
Wet AMD gains a new FDA-approved therapy as retina, glaucoma, and dry eye pipelines surge—plus AI, devices, and workforce trends reshaping care.
July was a busy month for ophthalmology, with a major wet age-related macular degeneration (AMD) approval, a wave of pipeline updates in retina and glaucoma, fresh thinking on dry eye disease, and continued debate over the specialty's workforce pressures.






